GEA
KRYS icon

Glen Eagle Advisors’s Krystal Biotech KRYS Stock Holding History

Glen Eagle Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29K Hold
5
– – ﹤0.01% 896
2025
Q4 		$1.23K Hold
5
– – ﹤0.01% 945
2025
Q3 		$883 Hold
5
– – ﹤0.01% 1011
2025
Q2 		$687 Hold
5
– – ﹤0.01% 963
2025
Q1 		$902 Hold
5
– – ﹤0.01% 943
2024
Q4 		$783 Hold
5
– – ﹤0.01% 994
2024
Q3 		$910 Hold
5
– – ﹤0.01% 1016
2024
Q2 		$918 Buy
+5
New +$839 ﹤0.01% 1009

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glen Eagle Advisors's KRYS Position: Q1 2026 in Review

Glen Eagle Advisors held its Krystal Biotech (KRYS) position steady in Q1 2026 at 5 shares worth $1.29K. The position accounts for ﹤0.01% of the portfolio, ranked #896.

Glen Eagle Advisors first reported a position in KRYS in Q2 2024 and has held it in 8 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Glen Eagle Advisors held 5 shares of Krystal Biotech worth $1.29K as of Q1 2026.
  • Glen Eagle Advisors left its Krystal Biotech share count unchanged in Q1 2026.
  • Krystal Biotech made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #896 holding.
  • Glen Eagle Advisors first reported a position in Krystal Biotech in Q2 2024 and has held it in 8 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.